| Monday, October 19, 2015, Day One |
| 10:00 - 11:30 AM |
Attendees are invited to move from room-to-room |
| Room |
Grand Ballroom BC |
Grand Ballroom FG |
| Session Title |
TRA-1. TOP RATED ABSTRACTS I
Click to view session |
TRA-2. TOP RATED ABSTRACTS II
Click to view session |
| 10:00 - 10:15 |
TRA-1-1 (DEC) TEST RESULTS IN LINE GRAPHS INSTEAD OF TABLES:..
TRA-1-1 (DEC) TEST RESULTS IN LINE GRAPHS INSTEAD OF TABLES: LESS CONFUSION WITHOUT DISTORTION
|
TRA-2-1 (QMTD) VALUE OF INDIVIDUALIZED INFORMATION IN..
TRA-2-1 (QMTD) VALUE OF INDIVIDUALIZED INFORMATION IN COST-EFFECTIVENESS ANALYSIS: WHEN IS AN OUTCOME PREDICTION MODEL WORTH USING?
|
| 10:15 - 10:30 |
TRA-1-2 (DEC) EMPIRICAL TESTING OF THE REGRET-BASED..
TRA-1-2 (DEC) EMPIRICAL TESTING OF THE REGRET-BASED THRESHOLD MODEL IN END OF LIFE CARE
|
TRA-2-2 (HSOP) BETTER EPIDEMIC CONTROL FOR FUTURE AFRICAN..
TRA-2-2 (HSOP) BETTER EPIDEMIC CONTROL FOR FUTURE AFRICAN EBOLA OUTBREAKS: DYNAMIC SIMULATION MODELING CALIBRATION AND ANALYSIS
|
| 10:30 - 10:45 |
TRA-1-3 (DEC) DO PATIENTS MIS-PREDICT FUTURE WELL-BEING IN..
TRA-1-3 (DEC) DO PATIENTS MIS-PREDICT FUTURE WELL-BEING IN DECISIONS ABOUT BREAST RECONSTRUCTION AFTER MASTECTOMY?
|
TRA-2-3 (HSOP) DEVELOPMENT OF A CLINICAL FORECASTING MODEL..
TRA-2-3 (HSOP) DEVELOPMENT OF A CLINICAL FORECASTING MODEL FOR DETECTING COMORBID DEPRESSION AMONG PATIENTS WITH DIABETES AND AN APPLICATION IN DEPRESSION SCREENING POLICYMAKING
|
| 10:45 - 11:00 |
TRA-1-4 (DEC) THE ASSOCIATION BETWEEN DECISION STYLES AND..
TRA-1-4 (DEC) THE ASSOCIATION BETWEEN DECISION STYLES AND APPRAISAL OF TREATMENT DECISION-MAKING: RESULTS OF THE ICANCARE STUDY
|
TRA-2-4 (HSOP) ESTIMATING THE PREVALENCE OF HEPATITIS C IN..
TRA-2-4 (HSOP) ESTIMATING THE PREVALENCE OF HEPATITIS C IN PENNSYLVANIA MEDICAID USING A MICROSIMULATION MODEL
|
| 11:00 - 11:15 |
TRA-1-5 (DEC) RACIAL CONCORDANCE AND PERCEPTION OF..
TRA-1-5 (DEC) RACIAL CONCORDANCE AND PERCEPTION OF HEALTHCARE PROVIDER'S COMMUNICATION SKILLS: DOES SOCIOECONOMIC STATUS MATTER?
|
TRA-2-5 (PSPE) HEALTH UTILITIES IN ADULTS WITH CHRONIC PAIN
TRA-2-5 (PSPE) HEALTH UTILITIES IN ADULTS WITH CHRONIC PAIN
|
| 11:15 - 11:30 |
TRA-1-6 (DEC) SHARED DECISION-MAKING PROGRAM LED TO IMPROVED..
TRA-1-6 (DEC) SHARED DECISION-MAKING PROGRAM LED TO IMPROVED RATES OF BLOOD PRESSURE CONTROL IN FEDERALLY QUALIFIED HEALTH CENTERS: THE OFFICE-GUIDELINE APPLIED TO PRACTICE (OFFICE-GAP) PROGRAM
|
TRA-2-6 (PSPE) DO STAKEHOLDER PREFERENCES FOR ENGAGEMENT IN..
TRA-2-6 (PSPE) DO STAKEHOLDER PREFERENCES FOR ENGAGEMENT IN PEDIATRIC ATTENTION-DEFICIT/HYPERACTIVITY DISORDER TREATMENT CORRELATE WITH REPORTED OUTCOMES? A BEST WORST SCALING EXPERIMENT
|
| 1:00 - 2:30 PM |
Attendees are invited to move from room-to-room |
| Room |
Grand Ballroom A |
Grand Ballroom B |
Grand Ballroom C |
| Session Title |
1A. ORAL ABSTRACTS: PREFERENCES AND DECISION MAKING IN COLORECTAL CANCER SCREENING
Click to view session |
1B. ORAL ABSTRACTS: STATED PREFERENCES AND DISCRETE-CHOICE EXPERIMENTS
Click to view session |
1C. ORAL ABSTRACTS: COST EFFECTIVENESS OF CARDIOVASCULAR DISEASE INTERVENTIONS
Click to view session |
| 1:00 - 1:15 |
1A-1 (DEC) PATIENT PERCEPTIONS ABOUT COLORECTAL CANCER..
1A-1 (DEC) PATIENT PERCEPTIONS ABOUT COLORECTAL CANCER SCREENING AFTER VIEWING A DECISION AID TARGETED TO OLDER ADULTS
|
1B-1 (PSPE) GOOD NEWS AND BAD NEWS: THE PERCEIVED VALUE OF..
1B-1 (PSPE) GOOD NEWS AND BAD NEWS: THE PERCEIVED VALUE OF WHOLE GENOME SEQUENCING INFORMATION
|
1C-1 (AHE) ALL TAKING SOME OR SOME TAKING NONE? ASSESSING..
1C-1 (AHE) ALL TAKING SOME OR SOME TAKING NONE? ASSESSING WHETHER DIFFERENT APPROACHES FOR MODELING DRUG COMPLIANCE AFFECT THE OPTIMAL DECISION FOR STATIN TREATMENT INITIATION
|
| 1:15 - 1:30 |
1A-2 (DEC) DETERMINANTS OF PATIENT INTENT AND PREFERENCE..
1A-2 (DEC) DETERMINANTS OF PATIENT INTENT AND PREFERENCE REGARDING COLORECTAL CANCER SCREENING: BASELINE FINDINGS FROM THE DATES (DECISION AID TO TECHNOLOGICALLY ENHANCE SHARED DECISION MAKING) STUDY
|
1B-2 (PSPE) A STATED CHOICE EXPERIMENT TO INVESTIGATE..
1B-2 (PSPE) A STATED CHOICE EXPERIMENT TO INVESTIGATE PREFERENCES FOR INFORMATION PROVISION IN NEWBORN BLOODSPOT SCREENING PROGRAMMES
|
1C-2 (AHE) COST-EFFECTIVENESS OF ANTIPLATELET DRUGS AFTER..
1C-2 (AHE) COST-EFFECTIVENESS OF ANTIPLATELET DRUGS AFTER PERCUTANEOUS CORONARY INTERVENTION
|
| 1:30 - 1:45 |
1A-3 (DEC) RANDOMIZED TRIAL OF A DECISION AID TO PROMOTE..
1A-3 (DEC) RANDOMIZED TRIAL OF A DECISION AID TO PROMOTE APPROPRIATE COLORECTAL CANCER SCREENING AMONG OLDER ADULTS
|
1B-3 (PSPE) THE DEVELOPMENT AND TESTING OF A DISCRETE..
1B-3 (PSPE) THE DEVELOPMENT AND TESTING OF A DISCRETE CHOICE EXPERIMENT QUESTIONNAIRE TO MEASURE INDIVIDUALS' PREFERENCES FOR HEALTH OUTCOMES AND MEDICAL EXPENDITURES
|
1C-3 (AHE) COST-EFFECTIVENESS OF TELEHOMECARE FOR CHRONIC..
1C-3 (AHE) COST-EFFECTIVENESS OF TELEHOMECARE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN CANADA
|
| 1:45 - 2:00 |
1A-4 (DEC) INFLUENCES ON PRIMARY CARE PROVIDERS'..
1A-4 (DEC) INFLUENCES ON PRIMARY CARE PROVIDERS' RECOMMENDATIONS FOR HYPOTHETICAL PROSTATE AND COLON CANCER SCREENING IN OLDER ADULTS: A WITHIN-SUBJECTS EXPERIMENT
|
1B-4 (PSPE) THE EFFECT OF FRAMING OF DEATH ON HEALTH STATE..
1B-4 (PSPE) THE EFFECT OF FRAMING OF DEATH ON HEALTH STATE VALUES OBTAINED FROM DISCRETE CHOICE EXPERIMENTS
|
1C-4 (AHE) PHARMACOGENOMICS IMPLEMENTATION: QUANTITATIVE..
1C-4 (AHE) PHARMACOGENOMICS IMPLEMENTATION: QUANTITATIVE COMPARISON OF EVIDENCE LEVELS FOR PHARMACOGENOMIC- VS. CLINICAL-BASED PERSONALIZED MEDICINE
|
| 2:00 - 2:15 |
1A-5 (DEC) IMPACT OF PERSONALIZED AND COMPARATIVE RISK..
1A-5 (DEC) IMPACT OF PERSONALIZED AND COMPARATIVE RISK INFORMATION ON DECISIONS ABOUT COLORECTAL CANCER SCREENING
|
1B-5 (PSPE) INVESTIGATING THE FRAMING-EFFECTS OF RISK..
1B-5 (PSPE) INVESTIGATING THE FRAMING-EFFECTS OF RISK ATTRIBUTES IN A DISCRETE CHOICE EXPERIMENT FOR A NATIONAL BREAST SCREENING PROGRAMME
|
1C-5 (AHE) STRATIFIED MEDICINE AND COST-EFFECTIVENESS:..
1C-5 (AHE) STRATIFIED MEDICINE AND COST-EFFECTIVENESS: STRONG INFLUENCE OF CHOICES IN MODELLING SHORT-TERM, TRIAL-BASED, MORTALITY RISK REDUCTION AND POST-TRIAL LIFE EXPECTANCY
|
| 2:15 - 2:30 |
1A-6 (PSPE) PREFERENCES FOR COLORECTAL SCREENING TESTS..
1A-6 (PSPE) PREFERENCES FOR COLORECTAL SCREENING TESTS AMONG A PREVIOUSLY UNSCREENED POPULATION
|
1B-6 (PSPE) VARIATION IN CAREGIVER PREFERENCES FOR..
1B-6 (PSPE) VARIATION IN CAREGIVER PREFERENCES FOR PEDIATRIC ATTENTION-DEFICIT/HYPERACTIVITY DISORDER TREATMENTS: A COMPARISON OF STRATIFICATION AND LATENT CLASS ANALYSIS
|
1C-6 (AHE) USING MODELING TO PROJECT OPTMIAL CAROTID..
1C-6 (AHE) USING MODELING TO PROJECT OPTMIAL CAROTID STENOSIS SCREENING PRACTICES
|
| 4:30 - 6:00 PM |
Attendees are invited to move from room-to-room |
| Room |
Grand Ballroom A |
Grand Ballroom B |
Grand Ballroom C |
| Session Title |
2D. ORAL ABSTRACTS: IMPROVING INFORMATION PRESENTATION AND PROCESSING
Click to view session |
2E. ORAL ABSTRACTS: ADVANCES AND APPLICATIONS IN QUANTITATIVE METHODS
Click to view session |
2F. ORAL ABSTRACTS: APPLIED HEALTH ECONOMICS AND PUBLIC HEALTH
Click to view session |
| 4:30 - 4:45 |
2D-1 (DEC) QUANTITATIVE ANALYSIS OF CONSUMER UNDERSTANDIN..
2D-1 (DEC) QUANTITATIVE ANALYSIS OF CONSUMER UNDERSTANDING, PREFERENCES, AND RESPONSES TO DRUG SAFETY MESSAGES
|
2E-1 (QMTD) A STATISTICAL APPROACH TO COST-EFFECTIVENESS..
2E-1 (QMTD) A STATISTICAL APPROACH TO COST-EFFECTIVENESS ANALYSIS UNDER UNCERTAINTY ABOUT THE WILLINGNESS-TO-PAY FOR HEALTH
|
2F-1 (AHE) MODELING THE COST-EFFECTIVENESS OF OPIOID..
2F-1 (AHE) MODELING THE COST-EFFECTIVENESS OF OPIOID AGONIST TREATMENT POLICY ALTERNATIVES IN CALIFORNIA'S PUBLICLY-FUNDED DRUG TREATMENT FACILITIES
|
| 4:45 - 5:00 |
2D-2 (DEC) BLOCK IT OUT! PRESENTING TEST RESULTS WITH..
2D-2 (DEC) BLOCK IT OUT! PRESENTING TEST RESULTS WITH CLEARLY DEFINED CATEGORIES INCREASES UNDERSTANDING OF THE RESULTS
|
2E-2 (QMTD) ANALYSIS OF DEPRESSION TRAJECTORY PATTERNS..
2E-2 (QMTD) ANALYSIS OF DEPRESSION TRAJECTORY PATTERNS USING COLLABORATIVE LEARNING
|
2F-2 (AHE) THE SCOPE OF VALUE AND OPPORTUNITY LOSS IN..
2F-2 (AHE) THE SCOPE OF VALUE AND OPPORTUNITY LOSS IN TREATING HEPATITIS C
|
| 5:00 - 5:15 |
2D-3 (DEC) CAN INTEGRATION OF MULTIMEDIA FEATURES INTO..
2D-3 (DEC) CAN INTEGRATION OF MULTIMEDIA FEATURES INTO DECISION AIDS IMPROVE PATIENT DECISION-MAKING? A SYSTEMATIC REVIEW AND META-ANALYSIS
|
2E-3 (QMTD) DATA-DRIVEN MODELING AND SIMULATION FOR THE..
2E-3 (QMTD) DATA-DRIVEN MODELING AND SIMULATION FOR THE DESIGN AND EVALUATION OF HIV VIRAL LOAD MONITORING POLICIES IN RESOURCE-LIMITED SETTINGS
|
2F-3 (AHE) INFORMING RESOURCE ALLOCATION DECISIONS IN..
2F-3 (AHE) INFORMING RESOURCE ALLOCATION DECISIONS IN HIV/AIDS: A CASE STUDY FOR BRITISH COLUMBIA, CANADA
|
| 5:15 - 5:30 |
2D-4 (DEC) COMPARISON OF BRIEF VS LONG PATIENT DECISION..
2D-4 (DEC) COMPARISON OF BRIEF VS LONG PATIENT DECISION AIDS ON DECISIONAL OUTCOMES IN RHEUMATOID ARTHRITIS
|
2E-4 (QMTD) DISTINGUISHING HIGH-RISK VERSUS LOW-RISK..
2E-4 (QMTD) DISTINGUISHING HIGH-RISK VERSUS LOW-RISK SUBGROUPS IN COMPARTMENTAL EPIDEMIC MODELS: WHERE TO DRAW THE LINE?
|
2F-4 (AHE) PROBABILISTIC MODEL-BASED PATTERN ANALYSIS OF..
2F-4 (AHE) PROBABILISTIC MODEL-BASED PATTERN ANALYSIS OF HEALTH RESOURCE USE AMONG PEOPLE LIVING WITH HIV/AIDS
|
| 5:30 - 5:45 |
2D-5 (DEC) THE IMPACT OF THE “ILLUSION OF EXPLANATORY..
2D-5 (DEC) THE IMPACT OF THE “ILLUSION OF EXPLANATORY DEPTH” ON HEALTH-RELATED DECISION MAKING PREFERENCES
|
2E-5 (QMTD) ACCOUNTING FOR INTERVAL CENSORING WHEN..
2E-5 (QMTD) ACCOUNTING FOR INTERVAL CENSORING WHEN ESTIMATING TIME-TO-EVENT CURVES FOR COST-EFFECTIVENESS ANALYSIS
|
2F-5 (AHE) A COMPARISON OF DIFFERENT APPROACHES IN..
2F-5 (AHE) A COMPARISON OF DIFFERENT APPROACHES IN MODELLING FOR THE CONDUCT OF COST-EFFECTIVENESS ANALYSES: A CASE IN CHILDHOOD FLU VACCINATION
|
| 5:45 - 6:00 |
2D-6 (DEC) PRACTICE MAKES PERFECT: A PRACTICE TRAVEL..
2D-6 (DEC) PRACTICE MAKES PERFECT: A PRACTICE TRAVEL DECISION INCREASES CONFIDENCE IN A SUBSEQUENT MEDICAL DECISION
|
2E-6 (QMTD) GENERALIZED PROPENSITY SCORE MATCHING WITH..
2E-6 (QMTD) GENERALIZED PROPENSITY SCORE MATCHING WITH MULTIPLE COHORTS: A CASE STUDY OF COMPARATIVE EFFECTIVENESS OF COMMON SECOND-LINE REGIMENS FOR NON-SMALL CELL LUNG CANCER IN THE US
|
2F-6 (AHE) COST EFFECTIVENESS OF INFLUENZA VACCINE..
2F-6 (AHE) COST EFFECTIVENESS OF INFLUENZA VACCINE OPTIONS IN US ELDERS
|
| Tuesday, October 20, 2015, Day Two |
| 10:30 - 12:00 PM |
Attendees are invited to move from room-to-room |
| Room |
Grand Ballroom A |
Grand Ballroom B |
Grand Ballroom C |
| Session Title |
3G. ORAL ABSTRACTS: PATIENT-PROVIDER INTERACTION AND COMMUNICATION
Click to view session |
3H. ORAL ABSTRACTS: CANCER OUTCOMES RESEARCH AND POLICY
Click to view session |
3I. ORAL ABSTRACTS: PATIENT PREFERENCES AND ENGAGEMENT
Click to view session |
| 10:30 - 10:45 |
3G-1 (DEC) DISHONESTY IN PATIENT DISCLOSURES TO..
3G-1 (DEC) DISHONESTY IN PATIENT DISCLOSURES TO HEALTHCARE PROVIDERS
|
3H-1 (HSOP) NOVEL BIOMARKERS TO TRIAGE WOMEN WITH MINOR..
3H-1 (HSOP) NOVEL BIOMARKERS TO TRIAGE WOMEN WITH MINOR CERVICAL LESIONS: QUANTIFYING THE COST-EFFECTIVENESS TRADEOFFS TO ENSURE FEASIBLE IMPLEMENTATION
|
3I-1 (PSPE) IMPACT OF MULTIPLE TEST OPTIONS ON INTENT-TO-S..
3I-1 (PSPE) IMPACT OF MULTIPLE TEST OPTIONS ON INTENT-TO-SCREEN AMONG A PREVIOUSLY UNSCREENED POPULATION
|
| 10:45 - 11:00 |
3G-2 (DEC) ARE PATIENTS BIASED AGAINST MINORITY AND..
3G-2 (DEC) ARE PATIENTS BIASED AGAINST MINORITY AND FEMALE PHYSICIANS? EVIDENCE THAT BIAS PREDICTS PHYSICIAN EVALUATIONS
|
3H-2 (HSOP) COMPARISON OF LUNG CANCER SCREENING GUIDELINES..
3H-2 (HSOP) COMPARISON OF LUNG CANCER SCREENING GUIDELINES WITH OTHER MAJOR PREVENTIVE CARE SERVICES IN SMOKERS
|
3I-2 (PSPE) WHY ARE SO MANY PATIENTS DISSATISFIED WITH..
3I-2 (PSPE) WHY ARE SO MANY PATIENTS DISSATISFIED WITH KNEE REPLACEMENT SURGERY? REFLECTIONS AND RESULTS FROM A MULTIPHASE MIXED METHODS STUDY IN BRITISH COLUMBIA
|
| 11:00 - 11:15 |
3G-3 (DEC) FACTORS AFFECTING PHYSICIANS' INTENTIONS TO..
3G-3 (DEC) FACTORS AFFECTING PHYSICIANS' INTENTIONS TO COMMUNICATE PERSONALIZED PROGNOSTIC INFORMATION TO CANCER PATIENTS AT THE END OF LIFE: AN EXPERIMENTAL VIGNETTE STUDY
|
3H-3 (HSOP) MODELING BREAST CANCER RISK IN YOUNGER WOMEN –..
3H-3 (HSOP) MODELING BREAST CANCER RISK IN YOUNGER WOMEN – A FIRST STEP IN THE DEVELOPMENT OF RISK-STRATIFIED MAMMOGRAPHIC SCREENING
|
3I-3 (PSPE) USE OF BEST-WORST SCALING TO ASSESS PATIENT..
3I-3 (PSPE) USE OF BEST-WORST SCALING TO ASSESS PATIENT PREFERENCES FOR REFRACTORY OVERACTIVE BLADDER TREATMENTS
|
| 11:15 - 11:30 |
3G-4 (DEC) VARIABILITY IN PHYSICIAN PROGNOSIS AND..
3G-4 (DEC) VARIABILITY IN PHYSICIAN PROGNOSIS AND RECOMMENDATIONS FOR LIFE SUSTAINING TREATMENT AFTER INTRACEREBRAL HEMORRHAGE
|
3H-4 (HSOP) VALUE OF ADDITION OF HPV VACCINATION TO ANAL..
3H-4 (HSOP) VALUE OF ADDITION OF HPV VACCINATION TO ANAL PRECANCEROUS LESION TREATMENT IN OLDER MSM—DO WE NEED FURTHER EVIDENCE?
|
3I-4 (PSPE) PATIENT BELIEFS AND PREFERENCES DO NOT EXPLAIN..
3I-4 (PSPE) PATIENT BELIEFS AND PREFERENCES DO NOT EXPLAIN VARIATION IN SUBSEQUENT TESTING AFTER INITIAL EVALUATION FOR ISCHEMIC HEART DISEASE
|
| 11:30 - 11:45 |
3G-5 (DEC) WHAT LEADS PARENTS TO SAY YES, NO OR MAYBE TO..
3G-5 (DEC) WHAT LEADS PARENTS TO SAY YES, NO OR MAYBE TO HUMAN PAPILLOMAVIRUS VACCINATION? THE ROLE OF PROVIDER RECOMMENDATION QUALITY
|
3H-5 (HSOP) PREDICTING UTILITY SCORES FOR MYELOFIBROSIS..
3H-5 (HSOP) PREDICTING UTILITY SCORES FOR MYELOFIBROSIS PATIENTS: MAPPING THE MYELOFIBROSIS SYMPTOM ASSESSMENT FORM AND MYELOPROLIFERATIVE SYMPTOM ASSESSMENT FORM TO THE EUROQOL-5D
|
3I-5 (PSPE) HEALTH UTILITY SCORES IN CHILDHOOD CANCER..
3I-5 (PSPE) HEALTH UTILITY SCORES IN CHILDHOOD CANCER SURVIVORS: INSIGHTS FROM THE CHILDHOOD CANCER SURVIVOR STUDY
|
| 11:45 - 12:00 |
3G-6 (PSPE) EARLY LESSONS FROM TESTING A “ONE SIZE FITS..
3G-6 (PSPE) EARLY LESSONS FROM TESTING A “ONE SIZE FITS ALL” DECISION AID FOR END-OF-LIFE CARE IN ADVANCED STAGE COPD
|
3H-6 (HSOP) A MODEL-BASED COMPARISON OF EVALUATION..
3H-6 (HSOP) A MODEL-BASED COMPARISON OF EVALUATION STRATEGIES FOR URINARY TRACT MALIGNANT TUMORS IN PATIENTS WITH ASYMPTOMATIC MICROSCOPIC HEMATURIA
|
3I-6 (PSPE) PREDICTING THE HUI3 AND EQ-5D FROM THE MOS-HIV..
3I-6 (PSPE) PREDICTING THE HUI3 AND EQ-5D FROM THE MOS-HIV IN PATIENTS WITH ADVANCED HIV
|
| 1:30 - 3:00 PM |
Attendees are invited to move from room-to-room |
| Room |
Grand Ballroom A |
Grand Ballroom B |
Grand Ballroom C |
| Session Title |
4J. ORAL ABSTRACTS: AFFECTIVE EXPERIENCES AND DECISION MAKING
Click to view session |
4K. ORAL ABSTRACTS: APPLICATIONS IN OUTCOMES RESEARCH AND POLICY
Click to view session |
4L. ORAL ABSTRACTS: APPLICATIONS OF VALUE OF INFORMATION AND COST EFFECTIVENESS ANALYSIS
Click to view session |
| 1:30 - 1:45 |
4J-1 (DEC) GRAPHIC WARNING LABELS ELICIT AFFECTIVE AND..
4J-1 (DEC) GRAPHIC WARNING LABELS ELICIT AFFECTIVE AND THOUGHTFUL RESPONSES FROM SMOKERS
|
4K-1 (HSOP) OPTIMAL TIMING OF DRUG SENSITIVITY TESTING FOR..
4K-1 (HSOP) OPTIMAL TIMING OF DRUG SENSITIVITY TESTING FOR PATIENTS ON FIRST-LINE TB TREATMENT IN INDIA
|
4L-1 (AHE) VALUE OF INFORMATION ANALYSIS TO EXPLORE THE..
4L-1 (AHE) VALUE OF INFORMATION ANALYSIS TO EXPLORE THE UNCERTAINTY OF AN EARLY IDENTIFICATION MODEL OF ALZHEIMER'S DISEASE
|
| 1:45 - 2:00 |
4J-2 (DEC) SIDE EFFECT PERCEPTIONS AND THEIR EFFECT ON..
4J-2 (DEC) SIDE EFFECT PERCEPTIONS AND THEIR EFFECT ON TREATMENT DECISIONS: A PSYCHOMETRIC INVESTIGATION
|
4K-2 (HSOP) CURRENT TREATMENT FOR CHRONIC HEPATITIS B..
4K-2 (HSOP) CURRENT TREATMENT FOR CHRONIC HEPATITIS B (CHB): A SYSTEMATIC REVIEW AND A NETWORK META-ANALYSIS
|
4L-2 (AHE) COST EFFECTIVENESS OF NOVEL ALZHEIMER'S..
4L-2 (AHE) COST EFFECTIVENESS OF NOVEL ALZHEIMER'S DEMENTIA DIAGNOSTICS
|
| 2:00 - 2:15 |
4J-3 (DEC) MEDICATION ACTIVATION INFLUENCES DECISIONS..
4J-3 (DEC) MEDICATION ACTIVATION INFLUENCES DECISIONS REGARDING TREATMENT ESCALATION
|
4K-3 (HSOP) BURDEN OF COMMUNITY-ACQUIRED CLOSTRIDIUM..
4K-3 (HSOP) BURDEN OF COMMUNITY-ACQUIRED CLOSTRIDIUM DIFFICILE INFECTION IN ONTARIO, CANADA: A POPULATION-BASED STUDY
|
4L-3 (AHE) VALUE OF PERFECT IMPLEMENTATION AND INFORMATIO..
4L-3 (AHE) VALUE OF PERFECT IMPLEMENTATION AND INFORMATION FOR ANTI-VEGF THERAPY FOR MACULAR DEGENERATION
|
| 2:15 - 2:30 |
4J-4 (DEC) EXPERIENCE NARRATIVES TARGETING THE DIRECTION..
4J-4 (DEC) EXPERIENCE NARRATIVES TARGETING THE DIRECTION OF BIAS REDUCE AFFECTIVE FORECASTING ERRORS
|
4K-4 (HSOP) CLASSIFICATION AND REGRESSION TREES (CART)..
4K-4 (HSOP) CLASSIFICATION AND REGRESSION TREES (CART) ANALYSIS FOR PREDICTING INFLUENZA
|
4L-4 (AHE) COST EFFECTIVENESS OF BRONCHIAL THERMOPLASTY..
4L-4 (AHE) COST EFFECTIVENESS OF BRONCHIAL THERMOPLASTY IN PATIENTS WITH SEVERE UNCONTROLLED ASTHMA
|
| 2:30 - 2:45 |
4J-5 (DEC) INCREASING VACCINE ACCEPTANCE: CAN WE INCREASE..
4J-5 (DEC) INCREASING VACCINE ACCEPTANCE: CAN WE INCREASE TRUST IN VACCINE SAFETY THROUGH EXPOSURE TO VAERS INFORMATION?
|
4K-6 (HSOP) USING AN ATRIAL FIBRILLATION DECISION SUPPORT..
4K-6 (HSOP) USING AN ATRIAL FIBRILLATION DECISION SUPPORT TOOL (AFDST) FOR THROMBOPROPHYLAXIS IN ATRIAL FIBRILLATION: IMPACT OF GENDER AND AGE
|
4L-5 (AHE) VALUE OF INFORMATION ANALYSES OF GOUT..
4L-5 (AHE) VALUE OF INFORMATION ANALYSES OF GOUT THERAPIES: USING A META-MODELING APPROACH
|
| 2:45 - 3:00 |
4J-6 (DEC) INCORPORATING INDIVIDUAL PATIENT PREFERENCES..
4J-6 (DEC) INCORPORATING INDIVIDUAL PATIENT PREFERENCES IN TREATMENT DECISION MODELING FOR BREAST CANCER
|
|
4L-6 (AHE) A COST-EFFECTIVENESS ANALYSIS OF MINIMAL..
4L-6 (AHE) A COST-EFFECTIVENESS ANALYSIS OF MINIMAL RESIDUAL DISEASE TESTING FOR THE MANAGEMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
|
| Wednesday, October 21, 2015, Day Three |
| 10:00 - 11:30 AM |
Attendees are invited to move from room-to-room |
| Room |
Grand Ballroom A |
Grand Ballroom B |
Grand Ballroom C |
| Session Title |
5M. ORAL ABSTRACTS: SHARED DECISION MAKING AND DECISION SUPPORT INTERVENTIONS
Click to view session |
5N. ORAL ABSTRACTS: ADVANCING EVALUATION METHODS AND FRAMEWORKS
Click to view session |
5O. ORAL ABSTRACTS: APPLICATIONS IN HEALTH SERVICES RESEARCH
Click to view session |
| 10:00 - 10:15 |
5M-1 (DEC) SHARED DECISION MAKING (SDM) IN PEDIATRIC TYPE..
5M-1 (DEC) SHARED DECISION MAKING (SDM) IN PEDIATRIC TYPE 1 DIABETES: EVALUATION OF DECISION COACHING WITH A PATIENT DECISION AID
|
5N-1 (DEC) DEVELOPMENT AND PILOT OF FOUR DECISION AIDS..
5N-1 (DEC) DEVELOPMENT AND PILOT OF FOUR DECISION AIDS FOR IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS IN DIFFERENT MEDIA FORMATS
|
5O-1 (AHE) RACIAL DISPARITIES ON EXPENDITURES OF..
5O-1 (AHE) RACIAL DISPARITIES ON EXPENDITURES OF PRESCRIPTION MEDICATION FOR MAJOR CHRONIC DISEASES IN THE U.S.: MEDICAL EXPENDITURE PANEL SURVEY 2011-2012
|
| 10:15 - 10:30 |
5M-2 (DEC) SYSTEMATIC REVIEW OF SHARED DECISION MAKING..
5M-2 (DEC) SYSTEMATIC REVIEW OF SHARED DECISION MAKING INTERVENTIONS FOR INDIVIDUALS WITH MENTAL HEALTH CONCERNS
|
5N-2 (PSPE) CHOOSING APPROPRIATE MULTI-CRITERIA DECISION..
5N-2 (PSPE) CHOOSING APPROPRIATE MULTI-CRITERIA DECISION ANALYSIS TECHNIQUE(S) TO SUPPORT HEALTH CARE DECISIONS: ISSUES AND CONSIDERATIONS
|
5O-2 (AHE) ONE YEAR HEALTHCARE COST AND UTILIZATION IN..
5O-2 (AHE) ONE YEAR HEALTHCARE COST AND UTILIZATION IN ADULTS WITH CHRONIC PAIN
|
| 10:30 - 10:45 |
5M-3 (DEC) INCREASING PATIENT CENTERED COMMUNICATION AND..
5M-3 (DEC) INCREASING PATIENT CENTERED COMMUNICATION AND DECISION MAKING IN PRIMARY CARE OFFICE VISITS: COMPARATIVE EFFECTIVENESS OF A NOVEL MULTIDIMENSIONAL INTERVENTION WITH AN EXISTING PATIENT ACTIVATION INTERVENTION
|
5N-3 (PSPE) A CHECKLIST FOR REPORTING VALUATION STUDIES OF..
5N-3 (PSPE) A CHECKLIST FOR REPORTING VALUATION STUDIES OF MULTI-ATTRIBUTE UTILITY-BASED INSTRUMENTS (CREATE)
|
5O-3 (HSOP) MOTIVATING PROCESS COMPLIANCE THROUGH..
5O-3 (HSOP) MOTIVATING PROCESS COMPLIANCE THROUGH INDIVIDUAL ELECTRONIC MONITORING: AN EMPIRICAL EXAMINATION OF HAND HYGIENE IN HEALTHCARE
|
| 10:45 - 11:00 |
5M-4 (DEC) TREATMENT SUMMARIES AND FOLLOW-UP CARE..
5M-4 (DEC) TREATMENT SUMMARIES AND FOLLOW-UP CARE INSTRUCTIONS FOR CANCER SURVIVORS: IMPROVING SURVIVOR SELF-EFFICACY AND HEALTH CARE UTILIZATION
|
5N-4 (QMTD) AN EFFICIENT HYBRID CALIBRATION APPROACH..
5N-4 (QMTD) AN EFFICIENT HYBRID CALIBRATION APPROACH COMBINING ARTIFICIAL NEURAL NETWORK METAMODELING AND BAYESIAN METHODS
|
5O-4 (HSOP) A NATURALISTIC EVALUATION OF A DIAGNOSTIC..
5O-4 (HSOP) A NATURALISTIC EVALUATION OF A DIAGNOSTIC SUPPORT SYSTEM FOR FAMILY PHYSICIANS
|
| 11:00 - 11:15 |
5M-5 (DEC) FIELD TESTING OF DECISION COACHING USING..
5M-5 (DEC) FIELD TESTING OF DECISION COACHING USING PATIENT DECISION AID WITH PARENTS FACING POTENTIAL BIRTH OF AN EXTREMELY PREMATURE INFANT
|
5N-5 (AHE) PREFERENCE AGGREGATION IN THE HEALTH UTILITIES..
5N-5 (AHE) PREFERENCE AGGREGATION IN THE HEALTH UTILITIES INDEX MARK 2 AND 3
|
5O-5 (HSOP) TRENDS IN STAGE-SPECIFIC INCIDENCE OF PROSTATE..
5O-5 (HSOP) TRENDS IN STAGE-SPECIFIC INCIDENCE OF PROSTATE CANCER IN NORWAY, 1980-2010: A POPULATION-BASED STUDY
|
| 11:15 - 11:30 |
5M-6 (DEC) USING THE OBSERVER OPTION5 MEASURE TO EVALUATE..
5M-6 (DEC) USING THE OBSERVER OPTION5 MEASURE TO EVALUATE THE EFFECT OF A NOVEL “OPEN COMMUNICATION” INTERVENTION ON SHARED DECISION-MAKING IN PRIMARY CARE APPOINTMENTS
|
5N-6 (AHE) A FRAMEWORK FOR PRIORITIZING RESEARCH..
5N-6 (AHE) A FRAMEWORK FOR PRIORITIZING RESEARCH INVESTMENTS IN PRECISION MEDICINE
|
5O-6 (QMTD) USING BAYESIAN EVIDENCE SYNTHESIS TO ESTIMATE..
5O-6 (QMTD) USING BAYESIAN EVIDENCE SYNTHESIS TO ESTIMATE FRACTURE RISK ASSOCIATED WITH HORMONAL THERAPY IN EARLY BREAST CANCER
|
